Navigation Links
CryoLife Announces Management Promotions

ATLANTA, Aug. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that Bruce G. Anderson has been promoted to vice president of U.S. sales and marketing, and that Richard C. Gridley has been promoted to vice president of international sales and marketing. Both men will report to Gerald B. Seery, senior vice president of worldwide sales and marketing. Additionally, the company has announced the promotion of Timothy M. Neja to vice president of laboratory operations. Mr. Neja will report to D. Ashley Lee, executive vice president, chief operating officer and chief financial officer.

In his new position, Mr. Anderson, 42, will be responsible for the U.S. direct sales force, U.S. marketing, and customer service. Mr. Anderson began his career at CryoLife in 1994 as a territory manager and has held increasingly important roles within the sales and marketing organization, most recently serving as senior director, U.S. sales and marketing. Prior to joining CryoLife, Mr. Anderson was with Dun and Bradstreet Business Credit Services.

Mr. Gridley, 37, will now manage sales and marketing in Canada, Asia- Pacific, and Central and South America. Mr. Gridley joined CryoLife in 2005 as marketing manager for BioGlue(R) Surgical Adhesive and most recently served as marketing manager, global bioadhesives. Previously, Mr. Gridley was with Global Link Logistics, Inc., Rusch Inc. and 3M Company.

Mr. Neja, 42, has most recently served as senior director of laboratory operations at CryoLife. In his new role, he will continue to be responsible for all laboratory operations, including tissue processing and BioGlue manufacturing, as well as purchasing and facilities management. Prior to joining CryoLife in 1997 as production manager, Mr. Neja was with Centeon.

"We are pleased to announce these well-deserved promotions within our management team," said Steven G. Anderson, CryoLife president and chief executive officer. "Bruce, Rich and Tim have each made substantial contributions to the success of the organization over the past several years, and we believe they will continue to enhance our ability to bring cutting-edge solutions to cardiac and vascular surgeons world-wide."

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH(R), a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom and Germany for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site:

Media Contacts:

D. Ashley Lee Katie Brazel

Executive Vice President, Chief Fleishman Hillard

Financial Officer and Phone: 404-739-0150

Chief Operating Officer

Phone: 770-419-3355

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLifes Earnings Per Share Increased 180 Percent to $0.14 in Second Quarter of 2008 from $0.05 in Second Quarter of 2007
2. CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results
3. CryoLifes BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery
4. CryoLife to Present at FBR Capital Markets Annual Spring Investor Conference
5. Harvey Morgan Joins CryoLife Board of Directors
6. CryoLife Conducts Surgeons Cardiac Allograft Symposium
7. CryoLife to Distribute FDA-approved Hemostatic Agent Under Private Label
8. CryoLife Closes on $15 Million Credit Facility with GE Healthcare Financial Services
9. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
10. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
11. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... Chapel Hill, N.C. (PRWEB) , ... June 27, ... ... of U.S. commercial operations for Amgen, will join the faculty of the ... will serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):